@article{AOB4695,
author = {Sema Nickbakhsh and John McLauchlan and E. Carol McWilliam Leitch},
title = {Evaluating “treatment as prevention” on the road to hepatitis C virus elimination},
journal = {Annals of Blood},
volume = {3},
number = {0},
year = {2018},
keywords = {},
abstract = {Fraser and colleagues (1) have recently published the results of a study modelling the direct acting antiviral (DAA) scale-up requirements needed to reduce hepatitis C virus (HCV) infection in people who inject drugs (PWID) within selected European sites. Such “treatment as prevention” strategies have been previously proposed to address the ambitious WHO HCV elimination target for 2030 (2), established in response to the world-wide exponential growth in HCV-associated liver disease which has occurred in the past few decades and is a leading cause of increased liver-related mortality (3).},
issn = {2521-361X}, url = {https://aob.amegroups.org/article/view/4695}
}